Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Florida Hospital Orlando
795
mi
from 43215
Orlando, FL
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Florida Hospital Orlando
795
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
NorthShore University HealthSystem-Evanston Hospital
283
mi
from 43215
Evanston, IL
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
NorthShore University HealthSystem-Evanston Hospital
283
mi
from 43215
Evanston, IL
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
139
mi
from 43215
Fort Wayne, IN
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
139
mi
from 43215
Fort Wayne, IN
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Spectrum Health Big Rapids Hospital
287
mi
from 43215
Big Rapids, MI
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Spectrum Health Big Rapids Hospital
287
mi
from 43215
Big Rapids, MI
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Mercy Health Saint Mary's
247
mi
from 43215
Grand Rapids, MI
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Mercy Health Saint Mary's
247
mi
from 43215
Grand Rapids, MI
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Mercy Health Mercy Campus
280
mi
from 43215
Muskegon, MI
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Mercy Health Mercy Campus
280
mi
from 43215
Muskegon, MI
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Cooper Hospital University Medical Center
418
mi
from 43215
Camden, NJ
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Cooper Hospital University Medical Center
418
mi
from 43215
Camden, NJ
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
2
mi
from 43215
Columbus, OH
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Oklahoma City
849
mi
from 43215
Oklahoma City, OK
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Oklahoma City
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
West Penn Hospital
165
mi
from 43215
Pittsburgh, PA
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
West Penn Hospital
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Roper Hospital
525
mi
from 43215
Charleston, SC
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Roper Hospital
525
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Central Vermont Medical Center/National Life Cancer Treatment
609
mi
from 43215
Berlin, VT
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Central Vermont Medical Center/National Life Cancer Treatment
609
mi
from 43215
Berlin, VT
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
University of Vermont College of Medicine
590
mi
from 43215
Burlington, VT
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
University of Vermont College of Medicine
590
mi
from 43215
Burlington, VT
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
344
mi
from 43215
Richmond, VA
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
460
mi
from 43215
Iowa City, IA
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Union Hospital of Cecil County
382
mi
from 43215
Elkton, MD
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Union Hospital of Cecil County
382
mi
from 43215
Elkton, MD
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Cancer Research Consortium of West Michigan NCORP
247
mi
from 43215
Grand Rapids, MI
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Cancer Research Consortium of West Michigan NCORP
247
mi
from 43215
Grand Rapids, MI
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Ellis Fischel Cancer Center
503
mi
from 43215
Columbia, MO
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Ellis Fischel Cancer Center
503
mi
from 43215
Columbia, MO
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Northwell Health NCORP
493
mi
from 43215
Lake Success, NY
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Northwell Health NCORP
493
mi
from 43215
Lake Success, NY
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Northwell Health- Center for Advanced Medicine
493
mi
from 43215
Lake Success, NY
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Northwell Health- Center for Advanced Medicine
493
mi
from 43215
Lake Success, NY
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Vidant Oncology-Kinston
429
mi
from 43215
Kinston, NC
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Vidant Oncology-Kinston
429
mi
from 43215
Kinston, NC
Click here to add this to my saved trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
NYP Weill Cornell Medical Center
479
mi
from 43215
New York, NY
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
NYP Weill Cornell Medical Center
479
mi
from 43215
New York, NY
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Sarasota Memorial Hospital
874
mi
from 43215
Sarasota, FL
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Sarasota Memorial Hospital
874
mi
from 43215
Sarasota, FL
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
344
mi
from 43215
Richmond, VA
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Saint Joseph's Hospital and Medical Center
1662
mi
from 43215
Phoenix, AZ
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Saint Joseph's Hospital and Medical Center
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Providence Saint Joseph Medical Center-Disney Family Cancer Center
1972
mi
from 43215
Burbank, CA
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Providence Saint Joseph Medical Center-Disney Family Cancer Center
1972
mi
from 43215
Burbank, CA
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center at Mount Zion
2108
mi
from 43215
San Francisco, CA
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center at Mount Zion
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Smilow Cancer Hospital Care Center at Saint Francis
553
mi
from 43215
Hartford, CT
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Smilow Cancer Hospital Care Center at Saint Francis
553
mi
from 43215
Hartford, CT
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
The Hospital of Central Connecticut
547
mi
from 43215
New Britain, CT
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
The Hospital of Central Connecticut
547
mi
from 43215
New Britain, CT
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Beebe Medical Center
429
mi
from 43215
Lewes, DE
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Beebe Medical Center
429
mi
from 43215
Lewes, DE
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health System - Christiana Hospital
385
mi
from 43215
Newark, DE
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health System - Christiana Hospital
385
mi
from 43215
Newark, DE
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Florida Hospital Orlando
795
mi
from 43215
Orlando, FL
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Florida Hospital Orlando
795
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Memorial Health University Medical Center
557
mi
from 43215
Savannah, GA
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Memorial Health University Medical Center
557
mi
from 43215
Savannah, GA
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
274
mi
from 43215
Chicago, IL
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Sudarshan K Sharma MD Limited-Gynecologic Oncology
285
mi
from 43215
Hinsdale, IL
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Sudarshan K Sharma MD Limited-Gynecologic Oncology
285
mi
from 43215
Hinsdale, IL
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital and Health Care Center
168
mi
from 43215
Indianapolis, IN
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital and Health Care Center
168
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Greater Baltimore Medical Center
342
mi
from 43215
Baltimore, MD
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Greater Baltimore Medical Center
342
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Union Hospital of Cecil County
382
mi
from 43215
Elkton, MD
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Union Hospital of Cecil County
382
mi
from 43215
Elkton, MD
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Baystate Medical Center
563
mi
from 43215
Springfield, MA
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Baystate Medical Center
563
mi
from 43215
Springfield, MA
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Michigan Cancer Research Consortium NCORP
164
mi
from 43215
Ann Arbor, MI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Michigan Cancer Research Consortium NCORP
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Hospital
157
mi
from 43215
Ann Arbor, MI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Hospital
157
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Saint Mary Mercy Hospital
168
mi
from 43215
Livonia, MI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Saint Mary Mercy Hospital
168
mi
from 43215
Livonia, MI
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Oakland
184
mi
from 43215
Pontiac, MI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Oakland
184
mi
from 43215
Pontiac, MI
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Lake Huron Medical Center
209
mi
from 43215
Port Huron, MI
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Lake Huron Medical Center
209
mi
from 43215
Port Huron, MI
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
660
mi
from 43215
Jackson, MS
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
660
mi
from 43215
Jackson, MS
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Cox Medical Center South
587
mi
from 43215
Springfield, MO
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Cox Medical Center South
587
mi
from 43215
Springfield, MO
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Nebraska Methodist Hospital
688
mi
from 43215
Omaha, NE
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Nebraska Methodist Hospital
688
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Women's Cancer Center of Nevada
1756
mi
from 43215
Las Vegas, NV
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Women's Cancer Center of Nevada
1756
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated:  12/31/1969
Cooper Hospital University Medical Center
418
mi
from 43215
Camden, NJ
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
Status: Enrolling
Updated: 12/31/1969
Cooper Hospital University Medical Center
418
mi
from 43215
Camden, NJ
Click here to add this to my saved trials